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contribution of SLC22A12 on 
hypouricemia and its clinical 
significance for screening purposes
Do Hyeon cha1, Heon Yung Gee  1, Raul cachau2, Jong Mun choi3, Daeui park  4, 
Sun Ha Jee5, Seungho Ryu6, Kyeong Kyu Kim7, Hong-Hee Won7, Sophie Limou8,9,10,11, 
Woojae Myung12, cheryl A. Winkler11 & Sung Kweon cho  7,13
Differentiating between inherited renal hypouricemia and transient hypouricemic status is challenging. 
Here, we aimed to describe the genetic background of hypouricemia patients using whole-exome 
sequencing (WeS) and assess the feasibility for genetic diagnosis using two founder variants in primary 
screening. We selected all cases (n = 31) with extreme hypouricemia (<1.3 mg/dl) from a Korean 
urban cohort of 179,381 subjects without underlying conditions. WES and corresponding downstream 
analyses were performed for the discovery of rare causal variants for hypouricemia. two known 
recessive variants within SLC22A12 (p.Trp258*, pArg90His) were identified in 24 out of 31 subjects 
(77.4%). In an independent cohort, we identified 50 individuals with hypouricemia and genotyped 
the p.Trp258* and p.Arg90His variants; 47 of the 50 (94%) hypouricemia cases were explained by only 
two mutations. four novel coding variants in SLC22A12, p.Asn136Lys, p.Thr225Lys, p.Arg284Gln, 
and p.Glu429Lys, were additionally identified. In silico studies predict these as pathogenic variants. 
This is the first study to show the value of genetic diagnostic screening for hypouricemia in the clinical 
setting. Screening of just two ethnic-specific variants (p.Trp258* and p.Arg90His) identified 87.7% 
(71/81) of Korean patients with monogenic hypouricemia. Early genetic identification of constitutive 
hypouricemia may prevent acute kidney injury by avoidance of dehydration and excessive exercise.
Uric acid (UA) is the final product of purine metabolism in humans1. After reuptake in the renal proximal tubule, 
only 10% of initially filtered UA is eliminated in the urine2. Serum UA level is determined by the balance between 
the rate of purine metabolism and clearance. Serum UA level converges to a normal distribution in general pop-
ulation3. At present, the heritability of serum urate has been estimated in several studies to account for 25% to 
60% of the variance in serum UA level4. Common variants within SLC2A9 and ABCG2 were reported to be highly 
associated with serum UA levels with an additional 28 genetic loci affecting serum urate level in a genome-wide 
association study (GWAS) of more than 140,000 individuals of European ancestry5.
Hypouricemia, defined as extremely low serum UA level, is a rare condition which can be affected by malnu-
trition, and by genetic defects in critical pathways involving UA synthesis and reabsorption system. Deficiencies 
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of xanthine dehydrogenase (XDH), Molybdenum Cofactor Sulfurase (MOCOS), purine nucleoside phospho-
rylase (PNP), and 5-phosphoribosyl-pyrophosphate (PRPP) are related to the defects in UA synthesis6. Renal 
hypouricemia (RHUC), with a prevalence of 0.19% to 0.53% in several studies, is diagnosed based on laboratory 
criteria as 1) hypouricemia (<2 mg/dL) and 2) increased fractional excretion of UA (>10%)7. RHUC is asympto-
matic and rarely identified unless an individual presents with severe renal symptoms including exercise-induced 
acute kidney injury (EIAKI), renal failure and nephrolithiasis8. Despite these important clinical implications, 
differentiating between inherited and transient hypouricemia is challenging because a low level of UA may reflect 
malnutrition status, which can be resolved by genetic screening using a panel with well-established genetic 
variants9.
Two types of RHUC have been currently reported: type 1 (OMIM: 220150) caused by mutations in 
SLC22A12 and type 2 (OMIM: 612076) caused by mutations in SLC2A9. A Japanese study first identified the 
protein-truncating p.Trp258* mutation in the SLC22A12 gene, which encodes a drug transporter in the renal 
proximal tubule10. Recently, coding variants in SLC22A12 and SLC2A9 causal for RHUC has been reported in 
various ethnic groups including Israeli-Arab, Iraqi-Jewish, and Roma populations in the Czech Republic and 
Slovakia7,11–15.
In this study, we investigated unrelated subjects with extremely low levels of UA using whole-exome sequenc-
ing (WES) to identify monogenic coding variants responsible for RHUC, which could be used for genetic screen-
ing of RHUC in Asians. After the discovery of candidate variants, we performed direct genotyping of the most 
frequent mutations (p.Trp258* and p.Arg90His) in SLC22A12 to replicate and quantify their contribution to 
RHUC in an independent Korean cohort, and to assess diagnostic feasibility of cost-effective genetic screening 
using these small subset of variants in hypouricemic patients.
Results
Hypouricemia prevalence and demographic information of 81 selected hypouricemic sub-
jects. The prevalence of extreme hypouricemia (serum UA < 1.3 mg/dL) is 0.083% for the KoGES urban 
cohort (148/179,318). A total of 81 individuals (31 subjects in the KoGES urban cohort and 50 additional subjects 
from KCPS-II cohorts) were genetically tested for RHUC diagnostic assessment. Their baseline characteristics 
are summarized in Table 1. The 81 participants with RHUC (UA 0.74 ± 0.24 mg/dL; age, 47 ± 10 years; BMI, 
23.3 ± 2.3 kg/m2; total cholesterol level, 189.2 ± 26.5 mg/dL) were healthy without chronic kidney disease, hyper-
tension, diabetes mellitus or other metabolic diseases and without any history of smoking or malnutrition.
Identification of coding variants in SLC22A12 by whole-exome sequencing. WES analysis was 
performed in 31 individuals with hypouricemia of the KoGES cohort (Fig. 1). The average depth coverage for 
these individuals was 85-fold. We performed variant calling and downstream filtering analyses assuming an 
autosomal recessive inheritance model. Coding variants in SLC22A12 were observed in 87.1% (27/31) of the 
individuals (Table 2). One subject was a compound heterozygote for SLC2A9 variants. In the remaining three 
Characteristics
Discovery 
group
Replication 
group Total
n = 31 n = 50 n = 81
Age (years) 47 ± 7 47 ± 12 47 ± 10
BMI* (kg/m2) 23.5 ± 2.0 23.1 ± 2.5 23.3 ± 2.3
Waist circumstance, cm 79.1 ± 6.3 79.5 ± 9.3 79.2 ± 7.0
Blood pressure, mmHg
Systolic 120 ± 13 117 ± 15 118 ± 14
Diastolic 74 ± 11 72 ± 11 73 ± 11
Smoking status
Never smokers, no. (%) 31 (100.00) 33 (34.00) 64 (79.0)
Ever smokers, no. (%) 0 (0) 17 (66.00) 17 (21.0)
Alcohol consumption
Never drinkers, no. (%) 19 (61.29) 18 (36.00) 37 (45.7)
Ever drinkers, no. (%) 12 (38.71) 32 (64.00) 44 (54.3)
Uric acid, mg/dL 0.77 ± 0.25 0.73 ± 0.24 0.74 ± 0.24
Total cholesterol, mg/dL 195.1 ± 25.4 185.5 ± 26.8 189.2 ± 26.5
Triglycerides, mg/dL 113.5 ± 66.6 113.8 ± 67.9 113.6 ± 67.0
Fasting glucose, mg/dL 90.2 ± 12.8 92.7 ± 21.2 91.7 ± 18.4
LDL cholesterol¶, mg/dL 115.5 ± 23.3 108.9 ± 22.0 111.4 ± 22.6
HDL cholesterol†, mg/dL 56.9 ± 12.3 55.0 ± 14.1 55.7 ± 13.4
Creatinine, mg/dL 0.78 ± 0.14 0.86 ± 0.17 0.83 ± 0.16
Table 1. Demographic characteristics. Values are presented as mean ± standard deviation (SD) for continuous 
data. *The body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared; 
¶LDL Cholesterol: Low-Density Lipoprotein Cholesterol; HDL Cholesterol: †High-Density Lipoprotein 
Cholesterol.
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individuals, variants within other genes were identified that appeared to have disease-causing potential and will 
be further investigated. 76% (24/31) individuals had variants previously reported in the Human Gene Mutation 
Database (HGMD) and the remaining 9.7% (3/31) exhibited novel missense mutations that had not been pre-
viously reported (Supplementary Table 3). 32.3% (10/31) of hypouricemia individuals were homozygous for the 
SLC22A12 p.Trp258* resulting in a premature stop codon, the most reported disease-causing variant to date. We 
also identified two homozygous individuals for the SLC22A12 p.Arg90His variants16. We found 12 compound 
heterozygous individuals for previously reported variants in the HGMD. In another individual, the p.Glu429Lys 
mutation was compound heterozygous with p.Trp258* in SLC22A12 (NIH17A8865148). Two novel SLC22A12 
missense variants, p.Thr225Lys and p.Arg284Gln, were identified as compound heterozygotes (NIH17A8798528). 
Finally, we identified the novel p.Asn136Lys variant in the compound heterozygous state with the previously 
reported p.Leu418Arg variant (NIH17K4930892) (Supplementary Table 3).
Figure 1. Overall flowchart for investigating novel variants associated with renal hypouricemia (DM: Diabetes 
Mellitus, HTN: Hypertension).
Number of 
Subjects (%)
Number of risk alleles in SLC22A12 Other than 
SLC22A12p.Trp258* p.Arg90His Others*
Discovery cohort, n = 31
10 (32.3%) 2 0 0
7 (22.6%) 1 1 0
2 (6.5%) 0 2 0
5 (16.1%) 1 0 1
3 (9.7%) 0 0 2
27 (87.1%) 4 (12.9%)
Replication cohort, n = 50
10 (20.0%) 2 0 0
22 (44.0%) 1 1 0
1 (2.0%) 0 2 0
10 (20.0%) 1 0 0
4 (8.0%) 0 1 0
47 (94.0%) 3 (6.6%)
Table 2. Distribution of SLC22A12 variants in discovery and replication cohorts. *p.Asn136Lys, p.Thr217Met, 
p.Gln382Leu, p.Leu418Arg, p.Glu429Lys or p.Arg477His. Distribution of SLC22A12 variants in 27 
hypouricemia individuals out of 31 in discovery cohort.
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The overall distribution of allele frequencies of the SLC22A12 variants within our study is shown in Fig. 2. 
The novel SLC22A12 variants were confirmed in the participant DNA samples by direct Sanger sequencing 
(Supplementary Fig. 1). Detailed properties of the four novel mutations in SLC22A12 are shown in Table 3 and 
Supplementary Table 3. This information was collected by querying several methods for functional prediction 
(Mutation Taster, Polyphen-2, SIFT, Condel). All four tools predicted the two SLC22A12 variants (p.Thr225Lys 
and p.Arg284Gln) reported in the NIH17A8798528 individual as deleterious. Amino acid sequence conservation 
was compared with R. macaque, M. musculus, C. lupus familiaris, and L. africana (Table 3). SLC22A12 p.Glu-
429Lys is not conserved in M. musculus and p.Asn136Lysd is not conserved in M. musculus, C. lupus familiaris, 
and L. africana.
Molecular dynamic prediction of SLC22A12 and novel variant location. The amino acid substitutions 
in SLC22A12 (10 variants) were considered for a molecular dynamic prediction analysis. The predicted functional 
impact of the amino acid change is illustrated in Supplementary Table 4. Our overall organization of the SLC22A12 
protein was similar to the molecular dynamics approach described by Clemencon et al.17. Steered dynamic simu-
lations of urate transport were performed with mutations in SLC22A12 and are presented in Fig. 3. Assessing the 
extent of the effect of the variants in the S set is difficult in a qualitative analysis due to the large changes observed 
during the molecular dynamics trajectory. p.Arg90His, p.Thr217Met, p.Thr225Lys, p.Trp258*, and p.Leu418Arg 
for SLC22A12 were predicted to alter protein structure defect. p.Arg284Gln and p.Arg477His were predicted to 
affect transport of uric acid. p.Asn136Lys and p.Gln382Leu for SLC22A12 were predicted to affect binding of urate. 
SLC22A12 p.Arg477His was predicted to both lower binding of urate and block the transportation pathway.
Utility of screening with two genetic SLC22A12 variants: c.774G > A (p.Trp258*) and c.269G > A 
(p.Arg90His). Among 50 hypouricemia individuals from the KCPS-II replication cohort, 47 individuals carried 
at least one of these two genetic variants (Supplementary Table 2): 10 individuals carried the c.774G > A (p.Trp258*) 
homozygous stop codon; one individual carried a c.269G > A (p.Arg90His) homozygous mutation; 22 individuals 
carried c.269G > A (p.Arg90His) and c.774G > A (p.Trp258*) in the compound heterozygous state; and 14 individ-
uals carried either c.269G > A (p.Arg90His) or c.774G > A (p.Trp258*) heterozygous variants.
Discussion
In this study, we comprehensively evaluated the contribution of SLC22A12 to severe hypouricemia through WES 
of 31 RHUC cases and replication of two implicated SNVs in 50 RHUC cases for a total of 81 unrelated Korean 
subjects. This is the first study to evaluate causal genetic variants for their diagnostic potential for RHUC. Overall, 
our study confirmed the importance of two mutations (p.Trp258* and p.Arg90His) in SLC22A12 for RHUC 
diagnosis found in 71/81(87.7%) of hypouricemia subjects.
Figure 2. (A) Allele frequency distribution in SLC22A12 variants from KoGES cohorts (n = 31). (B) A 
schematic diagram of the exonic location of SLC22A12 variants found in 27 subjects. Newly discovered coding 
variants are marked in red.
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Among the individuals exhibiting SLC22A12 mutations, we described four novel variants that had not been 
previously reported in the HGMD: p.Asn136Lys, p.Thr225Lys, p.Arg284Gln, and p.Glu429Lys. p.Asn136Lys 
(exon2) was located at the end of an intracellular loop, p.Thr225Lys (exon4) was present at the beginning of 
an extracellular loop, p.Arg284Gln (exon5) was localized in the largest extracellular loop, and p.Glu429Lys, in 
which the distal end of exon 7 and the first part of exon 8 are connected via splicing, was found to be within the 
membrane before an intracellular loop (Fig. 2B.)16. p.Asn136Lys occurred together with p.Leu418Arg in the case 
of NIH17K4930892; however, we could not determine cis or trans configuration. p.Thr225Lys: p.Arg284Gln and 
p.Glu429Lys:p.Trp258* were found in the compound heterozygous state, respectively in in NIH17A8798528 and 
NIH17A8865148. None of these variants were not found in Japanese (OMIM #220150, RHUC type 1)16,18–20. 
Further studies are needed to elucidate the pathogenicity of rare variants of unknown significance located within 
novel genes in six unexplained cases. Family-based WES studies for cases not explained by the two founder vari-
ants in SLC22A12 might identify additional monogenic genes that cause extremely low serum UA levels.
Gene
symbol Individual Chr
Base
position
Nucleotide 
changea
Amino 
acid
change
Amino acid
conservation Frequency  
in the
dbSNP 
databaseb
Frequency
in the
gnomAD
databasec
Mutation
Tastere
PP2
Humvarf SIFTg Condelh
Rhesus
macaque
Mus
musculus
Canis 
lupus
familiaris
Loxodonta
africana
SLC22A12
NIH17A8865148 11 64367362 c.1285G > A p.Glu429Lys Glu Gly Glu Glu
rs139140123
0.00005/5
(ExAC)
0.00008/1
(GO-ESP)
0.000044
(no 
homozygote)
DC Bn(0.37)
Tol
(0.05)
Neu
(0.463)
NIH17A8798528 11 64361119 c.674C > A p.Thr225Lys Thr Thr Thr Thr No No DC
Dam
(0.998)
Del
(0)
Del
(0.919)
11 64366008 c.851G > A p.Arg284Gln Arg Arg Arg Arg No
0.000019
(no 
homozygote)
DC Dam(0.527)
Del
(0.03)
Del
(0.542)
NIH17K4930892 11 64360256 c.408C > A p.Asn136Lys Asn Asp Asp Asp No
0.000004
(no 
homozygote)
PM Bn(0.345)
Del
(0)
Del
(0.553)
Table 3. Novel missense variants of SLC22A12 identified in individuals with renal hypouricemia via 
whole-exome sequencing. Abbreviations are as follows: Chr, chromosome; Bn, benign; Condel, consensus 
deleteriousness score of non-synonymous single nucleotide variants; Dam, damaging; DC, disease causing; 
Del, deleterious; Neu, neutral; PM, polymorphism; PP2, PolyPhen-2 prediction score Humvar; SIFT, sorting 
intolerant from tolerant; SNP, single nucleotide polymorphism; Tol, tolerant. acDNA mutations are numbered 
according to human cDNA reference sequence NM_144585.2 (SLC22A12). bdbSNP database (http://www.
ncbi.nlm.nih.gov/SNP). cgnomAD browser (http://gnomad.broadinstitute.org/). eMutation taster (http://www.
mutationtaster.org/). fPolyPhen-2 prediction score HumVar ranges from 0 to 1.0; 0 = benign, 1.0 = probably 
damaging (http://genetics.bwh.harvard.edu/pph2/). gSIFT (http://sift.jcvi.org/). hCondel (http://bbglab.
irbbarcelona.org/fannsdb/).
Figure 3. Residue mapping in the SLC22A12 predicted models.
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Hypouricemia is often regarded as an unrecognized or neglected disorder from a public health aspect21. The 
prevalence of renal stone due to excess of UA excretion is 6–7 times higher in patients with RHUC than in 
individuals with normal uric acid levels16. Evidence of oxidative stress has accumulated not only in EIAKI and 
renal stone but also in neurodegenerative disease (e.g., Parkinson’s disease) in persons with RHUC, reflecting 
the ability of UA to act as a powerful scavenger of approximately 60% of peroxide radicals in the plasma22–26. The 
anti-oxidative stress hypothesis is also supported by the results of Facheris et al., which show that the SLC2A9 
mutation, associated with lower serum UA, increases the risk for early onset of neurodegenerative diseases27. 
Early identification and intervention of hypouricemia (avoidance of hard exercise, adequate hydration, and 
pre-emptively taking XO inhibitors) may prevent adverse events, especially among military personnel and ath-
letics. XO inhibitor use (allopurinol or febuxostat) may be beneficial by lowering filtered UA. Screening of just 
two SLC22A12 variants (p.Trp258*/rs121907892 and p.Arg90His/rs121907896) for soldiers or athletics will pro-
vide early diagnosis of inherited RHUC and increase awareness among primary care physicians and medical 
care professionals (e.g. military, sport physicians, urologists) of the potential adverse health outcomes in at-risk 
individuals.
Here, we have shown that two Asian founder variants can provide a precision molecular diagnosis for 90% of 
inherited hypouricemia in the homogeneous Korean population. Recently, large scale WES have identified novel 
variants in SLC22A12 and SLC2A9 in individuals with European ancestry28. Like other genetic traits and condi-
tions, RHUC shows genetic allelic and locus heterogeneity. Given that genetic architecture and causal variants, 
particularly rare variants, differ among ethnic and racial groups, collaborative genomic research may identify 
novel, population-specific variants associated with RHUC. Considering all of the population-specific rare vari-
ants observed in hypouricemia patients in Japanese, Roma, and African populations, a cosmopolitan screening 
panel may yield high diagnostic power even among heterogeneous populations that present with complex genetic 
admixture.
In summary, this study indicates the cost-effectiveness of screening for just two variants to diagnosis mono-
genic renal hypouricemia, and its potential utility in at-risk groups.
Materials and Methods
Study participants. This study was approved by the institutional review board of the Kangbuk Samsung 
Hospital (IRB# KBSMC 2016-12-016). We screened the subjects in the Korean genome and epidemiology study 
(KoGES) – KoGES health examinee study (urban cohort) and KoGES twin and family study. Out of 179,318 indi-
viduals, we selected 31 (M:11, F:20) individuals of hypouricemia (<1.3 mg/dL) who exhibited no other syndromic 
features or secondary causes (chronic kidney disease, hypertension, diabetes mellitus or any other metabolic dis-
eases) and without any history of smoking. We also excluded people who have poor nutrition status. We obtained 
genomic DNA samples from the National Biobank of Korea29. In addition, 50 additional hypouricemic subjects 
without secondary causes were selected from the Korean Cancer Prevention Study (KCPS-II) cohort from the 
Severance Hospital, Seoul, Korea (IRB#4-2011-0277)30. Whole-exome sequencing (WES) was done in first 31 
individuals, whereas SNaPshot genotyping of two variants (p.Trp258* and p.Arg90His) within SLC22A12 was 
performed to assess its screening purpose for second 50 subjects.
A total of 81 hypouricemic patients were therefore recruited for this study. All patients had given informed 
consent before they were enrolled in the study, which was conducted according to the Declaration of Helsinki. 
The overall flowchart for this study is presented in Fig. 1.
DnA preparation and whole-exome sequencing. Genomic DNA was obtained from peripheral blood 
leukocytes. We checked the quality of the DNA with an OD260/280 ratio of 1.8–2.0 by 1% agarose gel electropho-
resis and PicoGreen® dsDNA Assay (Invitrogen, Waltham, MA, USA). SureSelect sequencing libraries were pre-
pared (Agilent SureSelect All Exon kit 50 Mb, Santa Clara, CA, USA) and the enriched library was then sequenced 
using the HiSeq 2500 sequencing system (Illumina, San Diego, CA, USA). Image analysis and base calling were 
performed with the pipeline software using default parameters. Mapping was done using the human reference 
genome assembly (GRCh37/hg19), and all variants were called and annotated using CLC Genomic Workbench 
(version 9.0.1) software (QIAGEN bioinformatics, Redwood city, CA, USA).
WES variant filtering analysis. We performed variant-filtering analysis assuming an autosomal reces-
sive or X-linked recessive pattern according to the predominantly observed inheritance mode in hereditary 
RHUC31. First, we systematically excluded variants with minor allele frequency (MAF) > 1%, which has been the 
conventional threshold for a rare variant, using dbSNP database (version 150), 1000 Genomes Projects phase 3 
data (2,504 individuals), Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org), and Genome 
Aggregation Database (gnomAD, http://gnomad.broadinstitute.org/)29. Second, variants present in the homozy-
gous or hemizygous state in in-house database consisting of 46 healthy Koreans without hypouricemia were 
excluded. Third, non-synonymous variants, small insertion/deletion (indel) or splice-site variants were selected. 
In the further analysis, we excluded single heterozygous variants so that only bi-allelic variants (homozygous, 
compound heterozygous, hemizygous for male) finally remained
Direct Sanger sequencing. Confirmation of called variants was conducted via direct Sanger sequencing. 
The DNA sequences spanning the variants were amplified using specific primers (Supplementary Table 1) and 
sequenced using an Applied Biosystems 3500xl genetic analyzer3500XL (Applied Biosystems, Foster City, CA, 
USA).
Snapshot method. The SNaPshot assay of rs121907896 (p.Arg90His) and rs121907892 (p.Trp258*) was 
performed according to the manufacturer’s instructions (ABI PRISM SNaPshot Multiplex kit, Foster City, CA, 
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USA). The analysis was carried out using GeneMapper software (version 4.0; Applied Biosystems). The primer 
sets for the SNaPshot assay are described in Supplementary Table 1.
In silico analysis of novel missense variants. Prior to the analysis, known pathogenic variants of 
SLC22A12 were screened in the Human Gene Mutation Database (HGMD®) as a public reference. For the newly 
discovered missense SLC22A12 variants, we checked if the mutated amino acid resides are highly conserved 
across the vertebrate orthologs using the UCSC Genome Browser (https://genome.ucsc.edu/). Given the role of 
the nitrogen excretion function in the evolutionary process, we identified amino acid sequences in several mam-
mals (Rhesus macaque, Mus musculus, Canis lupus familiaris, and Loxodonta africana) that share the urea cycle 
rather than direct UA excretion. Third, the prediction of the functional effect of missense variants was performed 
using the latest version of PolyPhen-2, SIFT, Condel, and Mutation Taster algorithms32–35.
In silico prediction of molecular dynamics. We initially predicted the structure of SLC22A12 using a 
homology modeling program, SWISS-MODEL (https://swissmodel.expasy.org/). The quality of predicted 3D 
structures was estimated on the basis of the geometrical analysis of the single model, global model quality estima-
tion (GMQE) score and qualitative model energy analysis (QMEAN)36. The GenBank accession number used for 
each amino acid sequence was NP_653186 for SLC22A12. After homology modeling was completed, we selected 
a suitable SLC2A3 X-ray structure for SLC22A12 (PDB ID: 4ZW9, SLC2A3)37,38. For the more stable molecular 
dynamics simulations, we used I-Tasser generated models39. All models were generated and made publicly avail-
able and can be recovered together with the statistics from the server site (https://zhanglab.ccmb.med.umich.
edu/I-TASSER/about.html). All graphical representations were made using the initial I-Tasser generated models 
to aid reproducibility. A qualitative evaluation of the mutation effect was conducted based on four simple criteria. 
Binding urate (U) indicates the effect of the mutation on binding or urate because of the exposure of the mutated 
residue to the vestibular region or the urate binding motif cavity and/or involves a polar/nonpolar mutation 
affecting the interaction with urate. The structural effect (S) was evaluated as an increase in the root mean square 
displacement (RMSD) deviation computed during 25 ns of molecular dynamics (after 25 ns of equilibration) 
measured against the conformations obtained during a 25 ns trajectory for the initial sequence using either a 
solvated model or a Feedback Restrained Molecular Dynamics model (FRMD). FRMD affords a simple protocol 
to maximally retain structural features during a molecular dynamics trajectory while minimizing distortions 
imposed by an external restrain40. The transport effect (T) indicates that the mutation intrudes into the vestibular 
area blocking the possible passage of urate and is assigned based on a reduction of the internal cavity volume. We 
used all the models to identify geometries compatible with the mutation extending the initial molecular dynamic 
trajectory for SLC22A12 (10 mutations) to 125 ns. All molecular dynamics calculations were performed using 
NAMD241 and the ff99SB force field in the NVT ensemble with typical settings (T = 298 K, 2fs integration time, 
12A cutoffs) obtained using QwikMD with default parameters to prepare the input files.
Data Availability
Before the official release, the data are available on reasonable request. The datasets generated during and/or an-
alysed during the current study are available from the corresponding author on reasonable request. The data will 
be available at CODA (Clinical & Omics Data Archive, http://coda.nih.go.kr).
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